PATH-29. CLINICAL SIGNIFICANCE OF TEMOZOLOMIDE-INDUCED SOMATIC HYPERMUTATION IN INITIALLY LOW-GRADE IDH-MUTANT DIFFUSE GLIOMAS

INTRODUCTION: Diffuse low-grade gliomas (DLGG) treated with temozolomide (TMZ) can develop somatic hypermutation. We present data on the incidence and prognostic importance of somatic hypermutation in IDH-mutant DLGGs. METHODS: We analyzed 120 patients treated on a phase II clinical trial of TMZ for...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Yu, Yao, Hilz, Stephanie, Grimmer, Matthew, Solomon, David, Choi, Serah, Wahl, Michael, Mazor, Tali, Hong, Chibo, Shai, Anny, J Phillips, Joanna, Villanueva-Meyer, Javier, McDermott, Michael, Haas-Kogan, Daphne, Taylor, Jennie, Butowski, Nicholas, Clarke, Jennifer, Berger, Mitchel, Molinaro, Annette, Chang, Susan, Costello, Joseph, Oberheim Bush, Nancy Ann
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2018
Gaiak:
Abstracts
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216686/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.685
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak